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Abstract 
Using a sunscreen-based photocage, we have demonstrated that it is possible to prevent 
photodegradation of a bioactive compound and to achieve its controlled photorelease. The 
concept has been proven linking avobenzone, one of the most important UVA blockers, to 
ketoprofen, which is a representative example of a photosensitive drug. 
Results and Discussion 
A number of bioactive compounds are used under conditions that involve their exposure 
to sunlight. This may result in progressive photodegradation, leading to loss of activity and/or 
the appearance of undesired photoproducts.1,2 In this context, topical drugs are now in 
widespread use to treat illnesses as diverse as bacterial or fungal infections, allergic rash, 
musculoskeletal trauma, etc. The fact that the drug is applied directly to the affected area allows 
concentrating its effects where needed. As a consequence, for an almost comparable 
effectiveness, local application shows a better safety profile than oral medication as it minimizes 
the spread of the active ingredients through the bloodstream to other parts of the body, thus 
reducing the risk of side effects such as gastric disturbances, generally associated with systemic 
delivery.3 However, the use of topical drugs is not innocuous and also presents drawbacks, the 
most important being related to the instability of some active constituents toward solar 
radiation. Sunlight exposure leads not only to degradation of the drug, thus decreasing its 
pharmacological effect, but also to the occurrence of chemical photosensitivity.4,5 This originates 
cutaneous side reactions such as phototoxicity or photoallergy, which typically appear as an 
exaggerated sunburn but they can also provoke severe and/or persistent reactions.4,5 
In this context, topical pain relievers such as non-steroidal anti-inflammatory drugs 
(NSAIDs) are available in most of the example of this family is ketoprofen (KP, Scheme 1) 
that is responsible for pronounced cutaneous photosensitization.6-10 Nowadays, the 
occurrence of severe side effects of drugs is a central public health problem that needs 
for innovative therapeutic approaches. Hence, specific measures have been taken for 
establishing their conditions of use, and explicit warnings on sun exposure and persistent 




Scheme 1. Tautomeric equilibrium of AB. Structure of AB-KP and photorelease of the latent AB and KP. 
 
It is well established that the in vivo photosensitizing properties of KP are linked to its 
reactivity in the UVA region of sunlight. Actually, the UV-Vis absorption spectrum of this 
drug exhibits two peaks, ie. an intense ππ* absorption centered in the UVC at 254 nm 
and a weaker UVA band of nπ* nature at ca. 330 nm (Figure 1 and S1).6, 8, 12 In this context, 
the development of sunscreen-based photocages (equivalent to covalently linked pro-
drug/pro-filter systems) could be considered a clever solution. This concept makes use of 
light-sensitive chemical moieties (photoremovable protecting groups, PPGs) to allow 
controlled and simultaneous release of the masked drug and the solar filter upon 
irradiation. This would be clearly advantageous over the mere mixture because it allows 
a controlled release of the two components.13 Photocages have become very popular 
because they provide spatial and temporal control over the activation of molecules 
triggered by light14-17 and have previously been employed for biological applications,15-19 
such as photocaged nucleotides,20, 21 20, 21 proteins,22-25 ions,26, 27 neurotransmitters,28 
pharmaceuticals,29-32 fluorescent dyes,32-34 or small molecules34-37. Interestingly, 
avobenzone (AB, 4-tert-butyl-4´-methoxydibenzoylmethane), which is one of the most 
important and representative UVA blockers present in commercial sunscreens and 
cosmetic formulations, contains two phenacyl moieties that could in principle work as 
PPGs to release carboxylic acids (in green, Scheme 1).14-17 Being a dibenzoylmethane 
derivative, AB suffers a keto-enol equilibrium, and the main enol tautomer is responsible 
for the large UVA absorption.38, 39 Therefore, the phenacyl structure of AB diketo form 
























in Scheme 1. This design should result in a remarkable combination capable to provide a 
phototriggered slow delivery of the drug together with that of its UVA protective shield. 
Thus, KP photoreactivity should be inhibited and the risk of adverse skin reactions 
minimized, as the AB absorption at ca. 350 nm is more than 200 times higher than that 
of KP (Figure S1). 
Here, we report on the synthesis and photochemical evaluation of this 
photoactivatable dyad (AB-KP, Scheme 1). The synthesis of AB-KP was performed 
straightforward. First, AB was brominated at the α position of the carbonyl groups by 
using N-bromosuccinimide under solvent free conditions; then, the resulting 
intermediate was reacted with the (S)-ketoprofen cesium salt to afford a 
diastereoisomeric mixture of the desired AB-KP, which was found to be almost 
exclusively in the diketo form. Full NMR and HRMS characterization is given in the 
Supplementary Information. The uncaging process was performed without separating 
the AB-KP diastereoisomers, because the new chiral carbon located on the AB moiety 
should be lost during the photochemical release, while the pharmacologically active (S) 










Figure 1. SSL-irradiation (from 0 to 30 min) of 9 x 10-5 M AB-KP in deaerated ethanol followed by UV 
absorption. Red dots shows the absorption of 7 x 10-4 M KP in EtOH. 
 
The pro-drug/pro-filter concept was easily checked by UV-Vis absorption 
spectroscopy monitoring the appearance of the characteristic UVA band of the enolic AB, 
centered at 355 nm, upon irradiation as diagnostic for the release process (Figure 1).38, 39 
A nitrogen flushed solution of AB-KP (9 x 10-5 M) in ethanol, selected as solvent for its 
hydrogen donor capability, was irradiated with simulated sunlight (SSL) provided by the 
filtered emission of a Xenon arc lamp. 
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As observed in Figure 1, the diketonic AB-KP band decreased with irradiation time 
concomitantly with the increase of the AB band, supporting formation of the enol 
tautomer of the filter. 
Due to the close absorption maxima of KP12 and AB-KP and the comparatively low 
molar absorption coefficient of KP at this wavelength, an accurate determination of the 
released drug required HPLC analysis, which was also achieved in a deaerated ethanol 
solution of AB-KP at higher concentration (1.1 x 10-3 M). Quantitation of the 
photoproducts was done by comparison with authentic samples of KP and AB. The HPLC 
traces revealed that the starting AB-KP peak disappeared over time giving actually rise to 
KP and AB (see Figure S2 of Supplementary Information). The time course of the process 
is shown in Figure 2. After 15 min, 30% of the initial AB-KP had reacted, while after 2h 
AB-KP was almost totally consumed. Interestingly, under the same experimental 
conditions KP was completely photolyzed in less than 30 min, clearly demonstrating the 
protecting role of the released AB filter (Figure S3, Supplementary Information). 
Irradiation of an aerated ethanol solution under the same experimental conditions did 
not lead to formation of AB (Figure S4, Supplementary Information), in agreement with 










Figure 2. Time-course of the photorelease of KP (orange line) and AB (grey line) through simulated sunlight 








































Figure 3. UV absorption changes for AB-KP (9 x 10-5 M) in aerated propylene glycol under SSL (from 0 to 35 
min). Inset: HPLC analysis for AB-KP (7 x 10-4 M). 
 
To go a step further and simulate the more viscous formulation compositions of 
topical creams, the photorelease was studied under air using propylene glycol as matrix. 
This way, the medium still presents hydrogen donor capability, but its lower diffusion-
controlled rate constant should disfavor the deactivation of excited states by oxygen. As 
shown in Figure 3, the AB band appeared as a function of SSL irradiation time. This was 




























Figure 4. Transient absorption spectra of (A) AB-KP in ethanol under N2, from 0.05 to 0.3 µs after the 355 nm 
laser pulse, and (B) ketoprofen and AB-KP (inset) from 3.1 to 15.8 ps after pump excitation. 
 






































































Finally, transient absorption spectroscopy was run to obtain direct information on the 
excited states involved in the photochemical process. Nanosecond laser flash photolysis 
experiments (Nd:YAG, 355 nm) were performed on a nitrogen bubbled ethanol solution 
of AB-KP (6.4 x 10-4 M). A transient absorption band centered at 400 nm appeared 
immediately after the pulse (Figure 4A) and decayed with a short lifetime of 0.2 µs 
without leading to further detectable species. According to the literature data, this band 
was assigned to the triplet-triplet transition of the avobenzone-like diketo form.38 At this 
time window, the signal of the KP-like triplet excited state at ca. 525 nm12, 41 was not 
observed. This could mean that it is not formed during the process or that it is indeed 
formed, but it disappears at a shorter timescale. Hence, ultrafast transient absorption 
spectroscopy was used to analyze the sub-nanosecond processes. Under these 
conditions, for an ethanolic solution of KP alone, the characteristic singlet-singlet 
transition at 580 nm was observed; after few picoseconds intersystem crossing with 
formation of the triplet excited state absorbing at 525 nm was also noticed (Figure 4B)42. 
By contrast, the 525 nm species was hardly detected in the case of the AB-KP (Figure 4B, 
inset). This is in agreement with the accepted mechanism involved in the uncaging of 
compounds using phenacyl as PPG.40 After light absorption, the triplet excited state of 
the phenacyl chromophore abstracts hydrogen from the solvent, and subsequently 
releases KP. Once formed, KP is protected by the AB enolic form that absorbs much more 





In summary, the present work has demonstrated that it is possible to develop 
photocages for protection and controlled release of bioactive compounds. The concept 
has been proven using sunscreen-based photocages for topical drugs, which are 
associated with a double beneficial effect: controlled release of the photosensitive active 
principle upon light exposure coupled with its protection from photodegradation and 
photoreactivity by the solar filter effect. As both ingredients are registered compounds 
already in use, the pro-drug/pro-filter concept could in principle be brought to practical 
application in a time- and cost- efficient way. 
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